ReviewCancers2023

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review.

Yiru Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.